Compare SOHU & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOHU | PROK |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.4M | 417.1M |
| IPO Year | 2000 | N/A |
| Metric | SOHU | PROK |
|---|---|---|
| Price | $15.68 | $2.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $20.00 | $6.25 |
| AVG Volume (30 Days) | 40.2K | ★ 1.4M |
| Earning Date | 11-17-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 5.11 | N/A |
| Revenue | ★ $576,757,000.00 | $744,000.00 |
| Revenue This Year | N/A | $918.66 |
| Revenue Next Year | $2.29 | N/A |
| P/E Ratio | $3.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.79 | $0.46 |
| 52 Week High | $16.45 | $7.13 |
| Indicator | SOHU | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 44.95 |
| Support Level | $14.94 | $2.04 |
| Resistance Level | $15.90 | $2.25 |
| Average True Range (ATR) | 0.68 | 0.19 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 80.60 | 45.90 |
Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.